L3VLUP
ProSign in

DNLI · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DNLIGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DNLI
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterDNLIGILD
Q3 20204 holders, $406m25 holders, $14.2bn
Q4 20207 holders, $1.6bn27 holders, $13.4bn
Q1 20217 holders, $1.2bn24 holders, $14.5bn
Q2 20215 holders, $1.7bn18 holders, $14.9bn
Q3 20216 holders, $1.1bn20 holders, $16.4bn
Q4 20214 holders, $709m20 holders, $16.8bn
Q1 20223 holders, $507m28 holders, $13.2bn
Q2 20225 holders, $481m26 holders, $13.6bn
Q3 20228 holders, $629m24 holders, $13.3bn
Q4 20226 holders, $766m32 holders, $21.1bn
Q1 20234 holders, $423m27 holders, $21.8bn
Q2 20236 holders, $760m24 holders, $20.7bn
Q3 20235 holders, $539m24 holders, $20.0bn
Q4 20238 holders, $577m22 holders, $21.5bn
Q1 20249 holders, $669m30 holders, $20.3bn
Q2 20249 holders, $829m28 holders, $18.5bn
Q3 20247 holders, $1.1bn29 holders, $24.2bn
Q4 20246 holders, $625m28 holders, $25.9bn
Q1 20255 holders, $422m33 holders, $32.0bn
Q2 20254 holders, $270m27 holders, $30.9bn
Q3 20255 holders, $333m23 holders, $29.4bn
Q4 20256 holders, $342m25 holders, $34.3bn
Q1 20267 holders, $372m25 holders, $38.5bn
Q2 20265 holders, $514m26 holders, $34.2bn
DNLI

Denali Therapeutics Inc

Holders
6
Reported value
$625m
Buyers
1
Sellers
5

Breadth -4 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
28
Reported value
$25.9bn
Buyers
14
Sellers
14

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DNLI (3)

Artisan Partners LP, Baillie Gifford & Co, Holocene Advisors LP

Only GILD (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →